

(Company No : 200301016113 (618533-M))

(Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS

		Individu	al period	Cumulat	Cumulative period		
	Note	Current Year Quarter 31-Mar-2022 RM'000	Preceding Year Corresponding Quarter 31-Mar-2021 RM'000	Current Year Quarter 31-Mar-2022 RM'000	Preceding Year Corresponding Quarter 31-Mar-2021 RM'000		
Revenue	8	18,295	12,956	18,295	12,956		
Operating expenses		(16,832)	(13,902)	(16,832)	(13,902)		
Net foreign exchange gain/(loss)	26	(108)	(95)	(108)	(95)		
Other income	26	118	103	118	103		
Operating profit/(loss)		1,473	(938)	1,473	(938)		
Finance costs	26	(334)	(353)	(334)	(353)		
Share of results of associates		(229)	-	(229)	-		
Profit/(loss) before taxation	8	910	(1,291)	910	(1,291)		
Income tax credit/(expense)	18	(372)	-	(372)	-		
Profit/(loss) for the period		538	(1,291)	538	(1,291)		
Profit attributable to:							
Owners of the parent	24	700	(1,122)	700	(1,122)		
Non-controlling interests		(162)	(169)	(162)	(169)		
Profit/(loss) for the period		538	(1,291)	538	(1,291)		
Earnings/(losses) per share (sen):							
Basic	24	0.46	(0.73)	0.46	(0.73)		
Diluted		N/A	N/A	N/A	N/A		
Number of ordinary shares ('000)	24	152,786	152,786	152,786	152,786		

These condensed consolidated income statements should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



(Company No : 200301016113 (618533-M))

(Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Individual period		Cumulative	e period		
	Preceding Year Current Year Corresponding Quarter Quarter		Current Year Corresponding		Current YearCorrespondingCurrent YearQuarterQuarterQuarter	
	RM'000	RM'000	RM'000	31-Mar-2021 RM'000		
Profit for the period	538	(1,291)	538	(1,291)		
Other comprehensive income:						
Foreign currency translation	(211)	2	(211)	17		
Total comprehensive income for the period	327	(1,289)	327	(1,274)		
Total comprehensive income attributable to:						
Owners of the parent	700	(1,122)	700	(1,122)		
Non-controlling interests	(373)	(167)	(373)	(152)		
Total comprehensive income for the period	327	(1,289)	327	(1,274)		

These condensed consolidated income statements should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



ADVENTA BERHAD (Company No : 200301016113 (618533-M))

(Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Note	Unaudited As at 2 31-Mar-2022 RM'000	Audited As at 31-Dec-2021 RM'000
ASSETS		
Non-current assets		
Property, plant & equipment	14,714	14,941
Intangible assets	55	55
Investment in associates	(208)	20
Deferred tax assets	833	833
	15,394	15,849
Current assets		
Inventories	22,021	22,921
Trade and other receivables 7	36,177	49,184
Tax recoverable	344	541
Cash and bank balances	7,681	7,805
	66,223	80,451
TOTAL ASSETS	81,617	96,300

These condensed consolidated statements of financial position should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



(Company No : 618533-M) (Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Note	Unaudited As at 31-Mar-2022 RM'000	Audited As at 31-Dec-2021 RM'000
EQUITY AND LIABILITIES			
Current liabilities			
Trade payables and other payables		11,426	22,133
Loans from director/former director		-	5,000
Lease liabilities		127	147
Bank borrowings	22	1,207	719
	_	12,760	27,999
Total liabilities	_	12,760	27,999
Equity			
Share capital		57,680	57,680
Foreign exchange reserve		11	2
Retained earnings	_	11,299	10,599
Equity attributable to owners of the parent Non-controlling interests		68,990 (133)	68,281 20
Total equity	=	68,857	68,301
TOTAL EQUITY AND LIABILITIES	=	81,617	96,300
Net assets per share (RM)	_	0.45	0.45

These condensed consolidated statements of financial position should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



(Company No : 200301016113 (618533-M))

(Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Non	<mark>-distributable</mark> D	<u>istributable</u>			
		Foreign			Non-	
	Share	exchange	Retained		controlling	Total
	capital	reserve	profits	Total	interests	equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Period ended 31 December 2021						
At 1 January 2021	57,680	59	(2,527)	55,212	(977)	54,235
Profit for the financial period	-	-	13,126	13,126	(128)	12,998
Other comprehensive income						
Foreign currency translation						
differences for foreign operations,						
representing total other						
comprehensive income	-	(57)	_	(57)	1,125	1,068
Total comprehensive income	-	(57)	-	(57)	1,125	1,068
At 31 December 2021	57,680	2	10,599	68,281	20	68,301
Period ended 31 March 2022						
At 1 January 2022	57,680	2	10,599	68,281	20	68,301
Profit for the financial period	-	-	700	700	67	767
Other comprehensive income						
Foreign currency translation differences for foreign operations, representing total other						
comprehensive income	_	9	_	9	(220)	(211)
Total comprehensive income	-	9	-	9	(220)	(211)
At 31 March 2022	57,680	11	11,299	68,990	(133)	68,857

These condensed consolidated statements of changes in equity should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



ADVENTA BERHAD (Company No : 200301016113 (618533-M))

(Incorporated in Malaysia)

FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

UNAUDITED ADJUSTED CONSOLIDATED STATEMENTS OF CASH FLOW

	Current Period to Date Ended 31-Mar-2022 RM'000	Corresponding Period to Date Ended 31-Mar-2021 RM'000
Cash flows from operating activities		
Profit/(loss) before tax	910	(1,291)
Adjustments for:		
Depreciation of property, plant and equipment	273	315
Impairment on inventories	-	2
Inventories written off	-	(3,194)
Interest expense	334	353
Interest income	(69)	(9)
Operating profit/ loss before working capital changes	1,448	(3,824)
(Increase)/decrease in inventories	900	2,664
(Increase)/decrease in receivables	13,007	1,635
(Decrease)/increase in payables	(15,707)	90
Cash used in operations	(352)	565
Taxes refund / (paid)	(159)	(16)
Net cash (used in)/from operating activities	(511)	549

These condensed consolidated statements of cash flow should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) FIRST QUARTER REPORT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2022

UNAUDITED ADJUSTED CONSOLIDATED STATEMENTS OF CASH FLOW

	Current Year to Date Ended 31-Mar-2022 Unaudited RM'000	Corresponding Year to Date Ended 31-Mar-2021 Audited RM'000
Cash flows from investing activities		
Purchase of property, plant and equipment	(46)	(278)
Proceed from disposal of plant and equipment	-	112
Investment in deferred development cost	_	(39)
Interest received	69	9
Net cash from/(used in) investing activities	23	(196)
Cash flows from financing activities		
Payment for lease liabilities	-	(6)
Net increase/(decrease) in borrowings	468	(530)
Interest paid	(334)	(353)
Net cash from/(used in) financing activities	134	(889)
Effects of foreign exchange rate changes	230	95
Net decrease in cash and cash equivalents	(124)	(441)
Cash and cash equivalents at beginning of financial period	7,805	15,174
Cash and cash equivalents at end of financial period	7,681	14,733
Cash and cash equivalents at end of financial period comprise: - Cash and bank balances	7,681	14,733

These condensed consolidated statements of cash flow should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021.

The audited financial statements of the Group for the year ended 31 December 2021 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2021.

2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2021 were no subject to any qualification.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect on the current quarter results.

5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

6. DIVIDENDS PAID

There was no dividend paid during the current quarter under review.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

7. TRADE AND OTHER RECEIVABLES

As at 31-Mar-22 RM ('000)	As at 31-Dec-21 RM ('000)
29,625	37,965
(3,790)	(3,790)
25,835	34,175
7,813	12,499
-	-
7,813	12,499
2,529	2,510
36,177	49,184
	31-Mar-22 RM ('000) 29,625 (3,790) 25,835 7,813 - 7,813 2,529

a) Trade Receivables

The Group's normal trade credit term ranges from 30 to 90 days (2021: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	As at 31-Mar-22 RM ('000)	As at 31-Dec-21 RM ('000)
Not past due	12,562	16,887
Past due: - Less than 30 days - 31 to 60 days - 61 to 90 days - More than 90 days	3,791 639 3,725 8,908	12,996 3,747 775 3,560
Less: Loss allowance - Collectively impaired - Individually impaired	29,625 (180) (3,610)	37,965 (180) (3,610)
Trade Receivable net	25,835	34,175



UNAUDITED NOTES TO FINANCIAL STATEMENTS

Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

8. SEGMENTAL INFORMATION

Healthcare: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which is for home and center-based treatments, serving both the domestic and export markets. This renal dialysis business was disposed of on 3 May 2021.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for the current quarter are as follow:

<u>Revenue</u>	Individual Qu	uarter Ended	Cumulative Q	uarter Ended
	31-Mar-22	31-Mar-21	31-Mar-22	31-Mar-21
<u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	18,295	12,985	18,295	12,985
Corporate	240	409	240	409
Elimination	(240)	(438)	(240)	(438)
Total	18,295	12,956	18,295	12,956
<u>PBT/(LBT) result</u>				
<u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	939	(1,171)	939	(1,171)
Corporate	(29)	(120)	(29)	(120)
Elimination	-	-	-	-
Total	910	(1,291)	910	(1,291)

9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

10. SIGNIFICANT EVENTS

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

11. CHANGES IN COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the financial period ended 31 March 2022.

12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

13. CAPITAL COMMITMENTS

There were no material capital commitments at the financial period ended 31 March 2022.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

14. **PERFORMANCE REVIEW**

	Individual Quarter Ended 1Q 2022	Individual Quarter Ended 1Q 2021	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	18,295	12,956	5,339	41%
Profit before tax / (Loss before tax)	910	(1,291)	2,201	170%

Sales revenue improved by 41% over FY 2022 first quarter, reflecting the recovery of the healthcare sector.

Profit before tax is RM910 thousand compared to the previous quarter's loss of RM1.2 million, a turnaround driven by the divestment of a loss making subsidiary and improved operations in current segments.

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Reporting Quarter 1Q 2022	Previous Quarter 4Q 2021	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	18,295	22,642	(4,347)	-19%
Profit Before Tax (PBT)	910	2,701	(1,791)	-66%

This quarter recorded a drop in revenue of RM4.3 million compared to the previous quarter and a lower profit before tax by RM1.79 million. In the current quarter, there is a change in hospitals' protocols and health policies as the country gradually embraces endemicity and we saw a shift in demand and usage of selected hospital products especially the personal protective equipment ("PPE") range. The closure of Mega Vaccination Centers ("PPV") has resulted in slower offtake of vaccination related supplies.

16. COMMENTARY ON CURRENT YEAR PROSPECTS

With the reopening of borders and recovering from Covid-19, there may be short-term headwinds as demand for certain Covid-19 related products taper off. However, we see increasing volumes and occupancy to pre-pandemic levels in the hospitals as the situation normalizes. Products for surgical and operating rooms is back in demand now. The Company has sustained the profitability trend this quarter and expects to continue for the current year unless current inflationary pressures and logistics challenges continue unabated.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

17. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.

18. TAXATION

The effective tax rate is higher than the statutory rate due to certain expenses being disallowed for tax purposes.

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-22	31-Mar-21	31-Mar-22	31-Mar-21
	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Income tax credit/(expense)	(372)	-	(372)	-
Deferred tax assets/(liabilities)	-	-	-	-
Total	(372)	-	(372)	-

19. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

20. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.

21. CORPORATE PROPOSALS

(i) <u>Proposed Private Placement and/or Proposed Shares Subscription</u>

The Company had on 8 Dec 2021 made an application to Bursa Malaysia for a Proposed Share Issuance of up to 20% of the total number of issued shares ("Proposed Share Issuance") and entered into a Subscription Agreement with Macquarie Bank Limited ("Macquarie") granting them the right to subscribe for up to 15 million of new Adventa Shares.

On 10 December 2021, the Company had obtained approval from Bursa Malaysia for the listing of and quotation for 30,557,154 new Adventa Shares ("Placement Shares") representing 20% of the Company's total number of issued shares.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

On 31 March 2022, the Subscription Agreement with Macquarie had expired and the Company has not placed out any placement shares to any third-party investor.

On 26 May 2022, the Company had made application to Bursa Malaysia for the extension of time ("EOT") of the Proposed Share Issuance for another 6 months from 9 June 2022 and allow all the Placement Shares to be issued to third-party investor(s) in view of the expiry of the Subscription Agreement with Macquarie.

The Company will sought shareholders's approval for 20% General Mandate ("20% General Mandate") at the forthcoming Annual General Meeting which is schedule to be held on 23 June 2022.

(ii) <u>Proposed Employee Share Scheme ("Proposed ESS")</u>

On 28 March 2022, the Company proposed to undertake the establishment of an employee share scheme, which comprises the proposed employee share option scheme ("Proposed ESOS") and the proposed share grant plan ("Proposed SGP"), of up to 15% of the total number of issued shares in the Company (excluding treasury shares of Adventa, if any) at any point in time during the duration of the employee share scheme, for eligible employees and Directors of the Company and its subsidiaries ("Eligible Persons"), which are not dormant, who fulfill the eligibility criteria as set out in the by-laws of the employee share scheme. (" Proposed ESS")

On 22 April 2022, Bursa Malaysia Securities Berhad had granted the approval for the implementation of the Proposed ESS and the scheme is currently pending shareholders' approval at the forthcoming Annual General Meeting ("AGM") which is schedule to be held on 23 June 2022.

Save for the above, there was no other corporate proposal announced as at the date of this interim report but pending completion.

22. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as of financial year ended 31 March 2022 as below.

	As at 31-Mar-22 RM ('000)	As at 31-Mar-21 RM ('000)
Current (Secured):		
Trade loan	1,207	-
Term Loan	-	1,000
Total Bank Borrowings	1,207	1,000



UNAUDITED NOTES TO FINANCIAL STATEMENTS

23. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

24. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

a. Basic

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-22	31-Mar-21	31-Mar-22	31-Mar-21
Profit attributable to ordinary equity holders of the parent (RM '000)	700	(1,122)	700	(1,122)
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	0.46	(0.73)	0.46	(0.73)

b. Diluted

There were no diluted earnings per share.

25. (LOSS) / PROFIT BEFORE TAX

(Loss) / profit before tax is stated after charging/(crediting):

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-22	31-Mar-21	31-Mar-22	31-Mar-21
	RM'000	RM'000	RM'000	RM'000
Other income	49	94	49	94
Interest income	69	9	69	9
Net foreign exchange loss/(gain)	(108)	(95)	(108)	(95)
Interest expenses	(334)	(353)	(334)	(353)



UNAUDITED NOTES TO FINANCIAL STATEMENTS

26. REALISED AND UNREALISED PROFITS/(LOSSES)

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is as follows:

	As at 31-Mar-2022	As at 31-Mar-2021
Group's total (Accumulated losses)/Retained profits:	RM'000	RM'000
Realised	16,659	(32,949)
Unrealised	(3,931)	(13,870)
Total Realised and unrealised	12,728	(46,819)
Less: Consol adjustments	1,429	43,170
(Accumulated losses) / Retained profits	11,299	(3,649)

27. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 27th May 2022.

By Order of the Board Adventa Berhad CHUA SIEW CHUAN Company Secretary MAICSA 0777689